# Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

> **NCT03338621** · PHASE2,PHASE3 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 455 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, MDR
- Tuberculosis
- Drug-Resistant Tuberculosis

## Interventions

- **DRUG:** Pretomanid
- **DRUG:** Bedaquiline
- **DRUG:** Moxifloxacin
- **DRUG:** Pyrazinamide
- **DRUG:** HRZE
- **DRUG:** HR

## Key facts

- **NCT ID:** NCT03338621
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2021-07-01
- **Final completion:** 2022-06-10
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338621, "Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03338621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*